Drug Trial Radar · NCT06550011
Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)
Last checked: Nov 19, 2026Latest source record: Feb 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
Aug 7, 2024
Primary completion
Jan 13, 2027
Study completion Jan 16, 2031
Sponsor
- Lead sponsor
- Avirmax Biopharma IncIndustry
- Sponsor type
- Industry
- First posted
- Aug 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 89 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This will be a clinical study to assess initial safety and tolerability of IVT ABI-110 in patients diagnosed with wet macular degeneration (wAMD), including symptomatic macular PCV.
Conditions
- Neovascular (Wet) AMD
Interventions
ABI-110 Low DoseDrug
Low dose. lower than the safety factor of 10 as recommended by the FDA
ABI-110 Medium DoseDrug
Medium dose
ABI-110 High DoseDrug
High Dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and TolerabilityTime frame: 52 weeks
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
California Retina Consultants
Bakersfield, California
Bay Area Retina Associates
Walnut Creek, California
Retina Consultants of Texas - San Antonio
San Antonio, Texas
Retina Consultants of Texas
The Woodlands, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.